Open AccessPPARγ agonists delay age‐associated metabolic disease and extend longevity
Author(s) -
Xu Lingyan,
Ma Xinran,
Verma Narendra,
Perie Luce,
Pendse Jay,
Shamloo Sama,
Marie Josephson Anne,
Wang Dongmei,
Qiu Jin,
Guo Mingwei,
Ping Xiaodan,
Allen Michele,
Noguchi Audrey,
Springer Danielle,
Shen Fei,
Liu Caizhi,
Zhang Shiwei,
Li Lingyu,
Li Jin,
Xiao Junjie,
Lu Jian,
Du Zhenyu,
Luo Jian,
Aleman Jose O.,
Leucht Philipp,
Mueller Elisabetta
Publication year - 2020
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.13267
Subject(s) - rosiglitazone , pioglitazone , medicine , endocrinology , biology , atrophy , inflammation , type 2 diabetes , senescence , longevity , insulin , peroxisome proliferator activated receptor , diabetes mellitus , receptor , genetics
Aging leads to a number of disorders caused by cellular senescence, tissue damage, and organ dysfunction. It has been reported that anti‐inflammatory and insulin‐sensitizing compounds delay, or reverse, the aging process and prevent metabolic disorders, neurodegenerative disease, and muscle atrophy, improving healthspan and extending lifespan. Here we investigated the effects of PPARγ agonists in preventing aging and increasing longevity, given their known properties in lowering inflammation and decreasing glycemia. Our molecular and physiological studies show that long‐term treatment of mice at 14 months of age with low doses of the PPARγ ligand rosiglitazone (Rosi) improved glucose metabolism and mitochondrial functionality. These effects were associated with decreased inflammation and reduced tissue atrophy, improved cognitive function, and diminished anxiety‐ and depression‐like conditions, without any adverse effects on cardiac and skeletal functionality. Furthermore, Rosi treatment of mice started when they were 14 months old was associated with lifespan extension. A retrospective analysis of the effects of the PPARγ agonist pioglitazone (Pio) on longevity showed decreased mortality in patients receiving Pio compared to those receiving a PPARγ‐independent insulin secretagogue glimepiride. Taken together, these data suggest the possibility of using PPARγ agonists to promote healthy aging and extend lifespan.